Oracle's capital spending is growing faster than its ability to justify the cost

Oracle reported a 30% jump in revenue and cloud infrastructure growth of 121% year-over-year, yet the stock fell nearly 2% on Friday as investors fixated on capital spending that now outpaces the cash the business generates.

This is the central tension in the AI infrastructure trade right now: the numbers look extraordinary, but the bill is arriving faster than the payoff, and the market is starting to ask whether the math works.

GameStop's CEO is betting his own money that the turnaround is more than a meme

Ryan Cohen added $20 million of his own cash to his GameStop stake on Friday, pushing his personal position toward $800 million as a company director also bought shares and the retailer announced it is reopening stores it had previously shut down.

Insider purchases at this scale are hard to dismiss as routine signaling: the person running the company spending $20 million of personal money is a direct statement that he believes the stock is worth more than the market currently thinks.

AstraZeneca's breast cancer trial failure is a serious crack in one of pharma's most-watched pipelines

AstraZeneca disclosed Friday that a late-stage trial of its breast cancer drug failed to hit its primary goal of slowing disease progression, a clinical setback that removes a key anticipated win from the company's cancer drug lineup.

Late-stage trial failures are the most expensive kind in drug development, because they come after years of investment and represent a door closing on a treatment that patients and investors had both been counting on.